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Resumo 
 
c-FLIP é uma proteína conhecida pela sua capacidade de se 
ligar ao DISC, onde compete com a procaspase-8 pela 
interação com FADD. No entanto, existem evidências que a 
sua isoforma longa consegue regular também o ciclo celular 
e mecanismos de proliferação. Para além disso, a atividade 
de c-FLIPL pode ser controlada por fosforilação. Assim, o 
objetivo deste estudo é perceber como a fosforilação no 
resíduo de serina 227 nesta proteína afeta a proliferação e 
ciclo celular. Neste estudo, observamos que a sobre-
expressão de c-FLIPL com uma mutação de serina para 
alanina no resíduo 227 levou a uma diminuição da 
capacidade proliferativa dessas células. O uso de citometria 
de fluxo permitiu verificar este decréscimo na capacidade 
proliferativa, assim como uma acumulação de células na 
fase G1 do ciclo celular aquando da sobre-expressão de 
S227A c-FLIPL. Os resultados obtidos sugerem que a sobre-
expressão de c-FLIPL controla a população celular através 
da transição G1/S, através da sua fosforilação no resíduo 
227. No entanto, mais estudos são necessários para se 
perceber a partir de qual mecanismo esta transição é afetada. 
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Abstract 
 
c-FLIP is a protein known for its capacity to bind to the 
DISC and compete with procaspase-8 for FADD 
interaction. However, published studies have shown that c-
FLIPL can regulate cell cycle and proliferation. Similarly to 
many other proteins, c-FLIP can be regulated by 
phosphorylation. Therefore, the aim of this work was to 
understand how the phosphorylation of S227 residue on c-
FLIPL affects cell cycle and cell proliferation. We observed 
that overexpression of phosphodeficient mutant c-FLIPL 
lead to a decrease in cell proliferation. Flow cytometric 
analysis confirmed this decrease, as well as an accumulation 
of cell at G1 phase of cell cycle, when overexpressing 
S227A c-FLIPL. Our results suggest that c-FLIPL 
overexpression controls cell population size by controlling 
the G1/S transition, via its phosphorylation. Nonetheless, 
further studies need to be done to understand which 
mechanism affects this transition. 
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1 Introduction 
The entire multicellular organism originates from a single cell, which divides and leads 
to an increase in cell number. Then, these cells receive different signals to differentiate. 
Proliferation and differentiation are two key processes required to build a functional 
organism.  
Although proliferation and differentiation are essential, the organism needs to remove all 
unwanted and damaged cells that appear continuously. This is done by death-inducing 
signals, that lead to cell death. Cell proliferation and cell death are processes that need 
constant regulation to be kept in equilibrium. This helps the organism to avoid physiological 
complications that might be life-threatening.  
The cell cycle can also control the balance between life and death of a cell. This control 
depends either on changes in the environment or signals that reach the cells. How the cell 
interprets this can cause cell cycle arrest or cycle progression until a cell divides into two 
cells.  
 
2  Review of the literature 
2.1  Cell cycle 
The cell cycle is a process dependent on a series of steps, which culminate in the division 
of a single cell into two daughter cells. The cell cycle is divided into three stages: interphase, 
mitosis and cytokinesis. In between or during these stages, there are also checkpoints, which 
allows the organism to check if cell division is being performed correctly (1).   
Before undergoing division, the cell needs to prepare itself by producing proteins and 
duplicating its deoxyribonucleic acid (DNA) content. This is done during interphase, which 
is divided into three phases: two gap phases (G1 and G2), and a synthesis phase (S) in between 
the G phases (figure 2.1). The G phases are both related with growth and preparation of the 
cell for the following steps. If the cell senses that it is not prepared for division during G1 
phase, or the environment is not ideal, this phase can be prolonged, or the cell can enter a 
special resting state, known as G0 (2). When conditions are favourable, the cell progresses 
to the S phase, a crucial step where DNA replication occurs. This stage is controlled by 
replication protein A (RPA), which interacts with single strand DNA, signalling a 
checkpoint, which ensures that the genetic material is correctly duplicated, before the cell 
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proceeds to mitosis (3). During G2, the cell continues to grow and producing proteins needed 
for division, and DNA condensation starts (4). 
 
Mitosis is composed of different phases: prophase, prometaphase, metaphase, anaphase 
and telophase, which prepare the cell for division. During this stage, the replicated DNA will 
continue to condense. The chromosomes will then bind to the formed mitotic spindle, 
aligning them at the equator of the cell. Before proceeding with separation of the sister 
chromatids, the cell checks if the spindle is well attached to the chromosomes, making sure 
that the division will be even. If everything is under control, the sister chromatids are 
separated, each of them reaching an opposite pole of the cell. Finally, the cell starts the 
division of the cytoplasm. The creation of two daughter cells is achieved at the cytokinesis 
stage (1). 
Since cell cycle is such an important part of life, it needs to be carefully controlled. For 
this to be accomplished, several proteins suffer changes in their levels or activity along the 
cycle, allowing progression through different cell cycle phases. 
 
2.1.1 Regulators of cell cycle 
The cyclin-dependent kinases (CDKs) are included in a family of serine/threonine protein 
kinases. There are various types of CDKs, but only four are activated during cell cycle and 
their activity is restricted to specific points of cell division (5). For instance, CDKs 4 and 6 
Figure 2.1 Cell cycle. The cell cycle begins when the cell is stimulated by a growth factor, which causes 
increase of cyclin D, that complexes with either CDK 4 or 6, and the cell progresses through G1 phase. G1/S 
transition requires activity of cyclin E-CDK2 complex, whereas cyclin A-CDK2 complex allows cell 
progression through S phase. Lastly, cyclin B-CDK1 complex are important for mitosis entry. 
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are activated at the G1 phase, CDK2 at G1 and S phase and CDK1 at mitotic phase (6). While 
active, CDKs can phosphorylate several targets. However, to be activated, these enzymes 
need to interact with activating proteins, known as cyclins. This association leads to 
formation of cyclin-CDK complexes, which are cell cycle stage specific (5). Although CDK 
levels are steady in the cell throughout cell cycle, the levels of cyclin change in a cyclical 
way, except for cyclin D, which expression needs growth factor stimulation (7). There are 
four different cyclins that can interact with CDKs to control cell cycle progression (figure 
2.1). Cyclin D interacts with CDKs 4 and 6, forming a complex that controls entry to G1 (8). 
Cyclin E will interact with CDK2 and controls progression from G1 into S phase (9). Cyclin 
A is needed during S phase and interacts with CDK2 (10). Finally, cyclin B, which is 
necessary for mitosis entry, interacts with CDK1 (figure 2.1) (11). When cyclins are no 
longer needed, they are marked for proteolysis by ubiquitin addition (12). 
Although cyclins are the major regulators of CDKs, CDKs are also regulated by 
phosphorylation on conserved threonine and tyrosine residues. CDKs 1, 4 and 2 require 
phosphorylation at a specific threonine to be fully activated (13). This phosphate addition is 
done by CDK-activating kinase (CAK) (14). There are also negative regulators of CDKs, 
such as Wee1-like protein kinase (Wee1) and myelin transcription factor 1 (Myt1) kinases, 
which is are kinase that phosphorylates CDKs to block their activity. However, this 
phosphorylation can be removed by a phosphatase known as cell division cycle 25 (Cdc25) 
(15). 
Other negative regulators of cell cycle are CDK inhibitors (CKIs). They can bind to either 
cyclin-CDK complex or to CDK alone, regulating their activity. Two different CKI families 
have been identified: the inhibitor of Cyclin-Dependent Kinase 4 (INK4) family and the 
CDK interacting protein/Kinase inhibitory protein (Cip/kip) family (6). The INK4 family 
includes p15, p16, p18 and p19, which specifically bind and inactivate CDK4 and CDK6 
(16). This occurs before cyclin binding, preventing this association to happen (16). The 
second family of CKIs is composed of p21, p27 and p57 (17). This CKI family is able to 
inactivate all cyclin-CDK complexes (18,19). Besides this function, cyclin-dependent kinase 
inhibitor 1 (p21) can also inhibit DNA synthesis. 
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2.1.2 Control of cell division and cell growth 
Mitogens are a group of proteins that include several growth factors (GFs), such as 
epidermal GF, platelet-derived GF, among others. This group of proteins can stimulate many 
types of cells to divide by acting in the G1 phase of the cell cycle (20). Entry to G1 phase 
depends on the formation of cyclin D-CDK4, or -CDK6, complexes. However, production 
of cyclin D only occurs upon mitogen stimulation (21). When a mitogen associates with a 
cell membrane receptor, it will activate a signalling pathway, which increases the expression 
of immediate early genes. Among these, there is one that encodes for c-Myc, a transcription 
factor, which increases the expression of delayed-response genes (1). Cell cycle progression 
is dependent on a series of positive feedback loops that control cyclin-CDKs levels, making 
sure the cell is prepared to complete the division process (22). Besides mitogens, cells are 
also stimulated by other growth factors, which stimulate cell growth, but not cell division. 
During cell division, the cell is also a target of survival factors, which supress apoptosis. 
 
2.1.2.1  G1/S transition 
The cell cycle progression not only depends on extracellular signals, but also requires 
dynamic changes in gene expression. These changes are controlled by CDK activities, which 
in turn influence cyclin levels. The cell cycle has three known transcriptional waves, which 
coincide with the cell cycle transitions (23). The first transcriptional wave occurs before 
G1/S and depends on the E2 transcription factor (E2F) family of transcription factors, 
together with DNA binding partners and pocket proteins, such as retinoblastoma protein 
(pRb) (24). These pocket proteins are important for cell cycle through interactions with E2F 
transcription factor (25). At early G1 phase, activator E2F proteins are bound and inhibited 
by pRb, repressing E2F activity at the promotor region of the gene. Upon phosphorylation 
of Rb by cyclin D-CDK4, E2F is released and can initiate transcription.  
Upon G1-S transcriptional activation, an “all-or-none switch” is created, which forces the 
cell to enter the cell cycle. This point is known as the restriction point, and it is characterised 
by increased cyclin-CDK activity and phosphorylation of pocket proteins. This allows initial 
activation of transcription of cyclin E. This activation is further increased by cyclin D, which 
increases its own transcription through positive feedback mechanisms (26). This causes 
accumulation of cyclin E and A, which then form a complex with CDK2, leading to its 
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activation. Upon G1/S transcription initiation and CDK2 activation, the cell progresses to S 
phase, where DNA replication starts.  
For cyclin/CDK activation, cyclin-dependent kinase inhibitor 1B (p27) and p21 have to 
be degraded to avoid its inhibition (17). It was recently suggested that p27 is the molecule 
responsible for inhibiting G1/S transition, and so, its abrupt degradation ensures S phase 
entry (27). Due to this, the activity of cyclin E/CDK2 must be high enough to overcome p27 
inhibition and mark this CKI for degradation (27). 
Once the cell has entered S phase, transcription must be inactivated, which is 
accomplished by negative feedback loops (figure 2.2). It has been proposed that CDK 
activity inactivates E2F-mediated transcription, since E2F1, member of the E2F family, is 
bound and phosphorylated by cyclin A-CDK2 (figure 2.2) (28). This promotes E2F1 
dissociation from DNA, and inactivation of its gene targets. Since the gene that encodes 
cyclin A is a target of E2F, this constitutes a negative feedback loop (28). Additionally, 
cyclin A-CDK2 activity is inhibited by p27, which is targeted for degradation by cyclin E-
CDK2 and cyclin A-CDK2. Thus, cyclin A-CDK2 inhibit E2F1 activity, which will no 
longer stimulate cyclin A and E genes, decreasing their protein production (29). 
Furthermore, protein levels of cyclin A and E will decrease due to degradation by p27 (30).  
Among the E2F family, there are some proteins that act as transcriptional repressors (31). 
These have been suggested to be part of additional negative feedback loops, which are 
important to inactivate G1/S transcription (32). (33) 
Figure 2.2 G1/S transition. a) When the cell enters S phase G1/S transcription must be inactivated, which 
involves negative feedback loops. b) p27 is targeted for degradation by both cyclin A-CDK2 and cyclin E-
CDK2. Higher activity of cyclin A-CDK2 results in phosphorylation of E2F1, which inactivates transcription. 
Adapted from Bertoli et al. 2013 (33). 
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2.1.2.2  G2/M transition 
As referred to previously, cell cycle progression is controlled by CDKs. The activity of 
these kinases is controlled by Cdc25, an activator of CDKs, and Wee1, which is an 
inactivator of CDKs. At the G2/M border only CDK1 is active. For this kinase to be active, 
it needs to associate with cyclin A or B, in animal cells (11). These cyclins accumulate during 
previous cell cycle phases, and are degraded when the cell reaches metaphase, which in turn 
causes inactivation of CDK1 (12). The cyclin B-CDK1 complex is actively kept in the 
cytoplasm, during G2 phase, making it unable to phosphorylate its nuclear targets. This is 
achieved by binding of the cyclin subunit to an exportin protein called chromosomal 
maintenance 1 (CRM1) (34). In turn, the import of the complex is done by importin β, also 
by interaction with the cyclin subunit (35). For the complex to be imported, cyclin B needs 
to be phosphorylated in its CRM1-binding site, blocking its binding to the exporter, allowing 
complex accumulation in the nucleus. The complex is kept inactive by two inhibitory 
phosphorylations catalysed by Wee1 and Myt1 (36). To activate CDK1, the inhibitory 
phosphorylations have to be removed by Cdc25 phosphatase (37). Additionally, CDK1 
needs to be phosphorylated by CAK, achieving its active state (38). This whole mechanism 
is further activated by a positive feedback loop involving Cdc25, which is phosphorylated 
by Cdk1, leading to higher Cdc25 activation (37). This mechanism ensures that the G2/M 
transition is completed, and the cell enters the mitosis phase. 
 
2.1.2.3  Cell cycle arrest 
Even though cell division is meticulously controlled, errors still occur during the process. 
One of the most important errors are related to DNA damage that might arise during 
replication, in the S phase. Nevertheless, the cell cycle has checkpoints, which are regulatory 
mechanisms that ensure that the cell cycle occurs without problems. These checkpoints occur 
during G1/S transition, G2/M transition and before anaphase. DNA is the major target during 
these checkpoints. If DNA damage is sensed by ataxia-telangiectasia mutated (ATM) or 
ataxia telangiectasia and Rad3-related (ATR), the cell cycle is arrested until the damage is 
repaired (39). Studies have shown that CDK1 is an important effector during G2 checkpoint. 
Upon DNA damage, ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and 
Rad3-related (ATR) protein kinases are recruited to the damaged site, and phosphorylate 
checkpoint kinase 1 (Chk 1) and checkpoint kinase 2 (Chk 2) (figure 2.3) (40). Chk1 is 
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required for cell cycle arrest due to damaged DNA, while Chk2 is required in response to 
unreplicated DNA (41,42), and both can phosphorylate Cdc25 (43). This phosphorylation 
creates a binding site for proteins of the 14-3-3 family, which sequester Cdc25 in the 
cytoplasm, leaving it unable to dephosphorylate CDK1 (44,45). However, other studies 
suggested that CDK1 is not the only protein necessary for mitotic delay (46). In this case, 
mitotic inhibitor kinase (MIK1) is an important target to induce delay. Overexpression of 
Chk1 was shown to cause MIK1-dependent mitotic arrest, suggesting MIK1 to act 
downstream of Chk1 (46). 
Another target of Chk1 and Chk2 is the tumour suppressor p53, which has the ability to 
induce either cell cycle arrest or cell death. As a response to stress, p53 is phosphorylated 
and activated (figure 2.3) (47). Typically, p53 is found at low levels in unstressed cells, since 
it is targeted for degradation by E3 ubiquitin-protein ligase Mdm2 (48). However, upon 
DNA damage, ATM and ATR will phosphorylate p53 (49). Therefore, Mdm2 will no longer 
mark p53 for degradation, leading to p53 accumulation and consequent activation of its 
target genes (50). Studies in human cells lacking p53 showed that G2 arrest still occurs. This 
shows that there are other pathways to arrest G2 phase that do not require p53 (51). On the 
other hand, overexpression of p53 leads to cell cycle arrest in G2 phase, even though the 
cells were not stressed (51).   
When p53 regulates G2 arrest, it activates genes that induce apoptosis, along with genes 
that induce growth arrest. Its major target is p21 gene, which is important for G1 arrest (52). 
When its transcription is activated, p21 production starts, thus blocking entry into the cell 
cycle, because this is a CKI that targets both cyclin E-CDK2 and cyclin A-CDK2 complexes 
(figure 2.3) (53). Although this process occurs during S phase, it can affect G1/S 
transcription. It was suggested that, under replication stress, Chk1 phosphorylates E2F6, 
inactivating it, which allows G1/S transcription to continue (54). G2 arrest is not achieved 
by p21 activation, since this protein binds poorly to CDK1 (55). However, studies have 
shown that p53 can induce transcription of other genes, such as GADD45 (56). The produced 
protein was shown to bind to CDK1 and to dissociate cyclin B-subunit, inactivating the 
complex (56). Other studies were performed to understand how p53 affects cyclin B1-CDK1 
complex (57,58). It was suggested that p53 may alter the cytoplasmic/nuclear shuttling of 
cyclin B1 to inhibit cyclin B1-CDK1 complex, however without any direct evidence (59). 
Several groups have reported that maintenance of G2 arrest after DNA damage requires 
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transcriptional repression mediated by Rb proteins (60,61). Among these studies, it was 
suggested that one of pRb targets during p53-dependent G2 arrest is CDK1 (61). There are 
several mechanisms to ensure that no errors remain in the cell. However, during cell cycle 
arrest, sometimes the damage is so severe that the repair mechanisms are unable to overcome 
it, and the cell undergoes apoptosis.  
 
2.2  Cellular FLICE inhibitory protein (c-FLIP) 
2.2.1 Isoforms 
FLIP was first identified while searching for death-effector domain (DED)-containing 
proteins that could regulate apoptosis (62). It was named as viral-FLIP (v-FLIP), since six 
different FLIP were found in γ-herpesvirus and molluscipoxvirus (63). It was shown that the 
protein turns infected cells resistant against cluster of differentiation 95 (CD95) and TNF-
related apoptosis-inducing ligand (TRAIL) receptor induced apoptosis (64). This is achieved 
Figure 2.3 Cell cycle arrest by DNA damage. DNA damage causes ATM/ATR activation, followed by 
Chk1/Chk2 activation. This causes p53 activation, which binds to p21 gene, stimulating p21 protein 
production.  Active p21 binds to cyclin E-CDK2 and cyclin A-CDK2, arresting cells in G1 (1) 
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because v-FLIPs have two DEDs, which can bind to Fas-associated death domain (FADD), 
an adaptor protein that associates with the death receptor. This interaction interferes with the 
interaction of FADD with procaspase-8, an inactive initiator caspase needed for apoptosis 
signalling, and inhibits procaspase-8 activation (64).  
Shortly after the discovery of v-FLIPs, its mammalian homologue was described and 
termed c-FLIP (65). Three different isoforms were discovered: c-FLIP long (c-FLIPL, 
55kDa), c-FLIP short (c-FLIPS, 27kDa) and c-FLIP Raji (c-FLIPR, 25kDa) (figure 2.4) 
(65,66). Interestingly, all these isoforms are encoded by CASP8 and FADD-like apoptosis 
regulator  (CFLAR) gene and generated from alternative splicing (66). Even though each 
isoform undergoes different processing, their two DEDs are similar. Compared to the other 
c-FLIP isoforms, the long one has an additional caspase-like domain, which is catalytically 
inactive due to replacement of a cysteine residue within the Gln-Ala-Cys-X-Gly-motif and 
a histidine within the His-Gly-motif (67). The short isoforms have a short C-terminal tail of 
19 and 17 amino acids for c-FLIPS and c-FLIPR, respectively (66).  
Since c-FLIP has in its structure DEDs, it competes with procaspase-8 for FADD 
interaction at the death-inducing signalling complex (64). Although v-FLIP and c-FLIP have 
been shown to have anti-apoptotic properties, some studies have shown that the long form 
can act as an activator of apoptosis.  (68) 
 
2.2.2 Regulation of protein levels 
The functions of c-FLIP in the cell are highly dependent on their cytoplasmic protein 
levels (69). Its levels can be controlled in several ways: protein synthesis, protein 
degradation, posttranslational modifications (PTMs) and subcellular localisation (65,70–75). 
Figure 2.4 c-FLIP isoforms. Schematic representation of all c-FLIP isoforms and cleavage products. p20 
and p12 are the inactive caspase-like domains of c-FLIPL. Asp198 and Asp376 are the cleavage sites, which 
lead to generation of p22-FLIP and p43-FLIP, respectively (68). 
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Protein synthesis begins with a gene being transcribed into a messenger RNA (mRNA), 
which is in turn translated into a polypeptide and folded into a specific conformation, 
producing a mature protein. Although c-FLIP is constitutively expressed in different normal 
cells, its gene expression can be controlled by a number of stimuli (76). The CFLAR gene 
expression is enhanced by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
and p53, for instance, causing higher amount of protein synthesis (70,77). On the other hand, 
CFLAR transcription is supressed by c-Myc and forkhead box O3 (Foxo3) (72,78). So, 
depending in which signals reach the targeted cell, c-FLIP can be produced in higher or 
lower levels than normal. 
Proteins can be marked for degradation, another process that helps controlling protein 
amount. This process is carried out by the 26S proteasome, hydrolysing the targeted protein 
into smaller polypeptides, which are then released and reused by the cell, if needed. It was 
shown that c-FLIPs is degraded by this mechanism (71). In addition, c-FLIPS has been 
proven to have a shorter half-life that c-FLIPL. This different stability between c-FLIP 
isoforms has been associated with differences between their C-terminal region. c-FLIPS has 
two crucial lysines in its C-terminal tail, which makes it more sensitive proteasomal 
degradation, when compared to other isoforms (79). 
PTMs can also affect c-FLIP levels. PTMs are achieved by addition of a molecule or 
small protein onto the target protein, which will have distinct outcomes. Ubiquitination is a 
PTM which marks a protein for degradation (80). The added protein is named ubiquitin, and 
it bind to lysine residues of the target molecule. Ubiquitin can form chains, or it can be added 
as a monomer (81). After addition of a ubiquitin chain to a lysine residue in a three-step 
enzyme cascade, a recognition step is performed by ubiquitin receptors. These receptors are 
able to distinguish different kinds of ubiquitin chains, which can lead to different outcomes 
in cells (73). As mentioned before, c-FLIPS has two lysines (K192 and K195) in its C-
terminal region. These lysines make it more sensitive for proteasomal degradation, since 
ubiquitin is added to these residues (79). It was also shown that c-FLIPL can be degraded 
upon tumour necrosis factor alpha (TNF-α) stimulation by the E3 ligase Itch, an enzyme 
needed for ubiquitin addition (82). Also, c-FLIPS was shown to be ubiquitinated when 
mamalian target of rapamycin (mTOR) complex 2 is inhibited (83). 
Besides ubiquitination, there are other PTMs. Protein phosphorylation and 
dephosphorylation are one of the most important PTMs in signalling pathways mediated by 
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external signals. Phosphorylation of a protein means addition of a phosphate group into one 
of these three hydroxyamino acids: serine (S), threonine and tyrosine. This reaction is 
achieved by transfer of a terminal phosphate group from ATP to the amino acid side chain 
of the target residue, and it is catalysed by protein kinases (84). Phosphorylation causes 
conformational changes in the modified protein, which can, for example, increase or 
decrease its activity or ability to interact with other molecules (85). To oppose protein kinase 
activity, multicellular organisms have protein phosphatases, which are able to remove a 
phosphate group from proteins, altering the target protein activity or interactions (86). c-
FLIPL can be phosphorylated by Ca
2+/calmodulin-dependent protein kinase II (CaMKII), 
promoting its recruitment to the death-inducing signalling complex (DISC) (74). Protein 
kinase C (PKC) phosphorylates c-FLIPs at S193, a common phosphorylation site of all c-
FLIP isoforms. Due to the proximity of S193 to K192 and K195 in c-FLIPS, it was explored 
if these PTMs would influence each other. It was shown that disruption of S193 
phosphorylation increased ubiquitination, affecting the half-lives of the short isoform (87). 
Also, S273 was reported to be phosphorylated by PI3K/Akt, resulting in degradation of c-
FLIPL during macrophage activation (88). 
The cell is divided in several compartments, and so, they can be used to store proteins in 
one place, changing their local concentration and kinetics. c-FLIP activity is believed to be 
controlled by changes in its subcellular localisation (75,89). Although it was thought that c-
FLIP was only localised in the cytoplasm due to its anti-apoptotic function, it was shown 
that it can also be expressed in the nucleus, because c-FLIPL has in its amino acid sequence 
two nuclear localisation signals (NLSs) and a nuclear export signal (NES) (75,89). The NLSs 
was shown to be important for c-FLIP nuclear localisation, because mutated NLS leads to 
no c-FLIP in the nucleus (75,89). 
Another way of c-FLIP level control is by proteolysis. This is achieved by proteases, such 
as caspases, and they are able to cleave c-FLIP into smaller fragments (90). This occurs 
because c-FLIPL has two aspartic cleavage sites, D196 located between DED2 and the 
caspase-like domain, and D376 in the middle of the caspase-like domain (65,91). The 
cleavage is done by caspase-8, after its activation and interaction with c-FLIPL (65). When 
cleaved at D376, FLICE-like inhibitory protein subunit 43 (p43-FLIP) is produced, but only 
from c-FLIPL (figure 2.4). Cleavage at the D196 residue produces FLICE-like inhibitory 
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protein subunit 22 (p22-FLIP) (figure 2.4), which can be obtained from all c-FLIP isoforms, 
which can induce NF-κB activation (91,92),. 
 
2.2.3 Functions of c-FLIP 
2.2.3.1  Apoptosis 
A tight control of c-FLIP is required, since this protein can affect different cell processes. 
When it was first discovered, FLIP was associated to apoptotic functions as an inhibitor of 
death receptor (DR)-mediated apoptosis. However, recent studies showed that it has 
functions not related to apoptosis. In order to inhibit DR-mediated apoptosis, c-FLIP needs 
to be recruited to the DISC via DED interactions (65). The short isoforms of c-FLIP, when 
bound to the DISC, are able to inhibit procaspase-8 activation and block CD95- or TRAIL-
induced apoptosis (65,91). Even though this function of the short isoform is clear, c-FLIPL 
function in apoptosis lacks consent. It was shown that the long isoform can have anti-
apoptotic function, similar to c-FLIPS/R, when expressed at high levels (91). However, 
endogenous expression of c-FLIPL makes it act as a pro-apoptotic molecule (93). This is 
mediated by formation of a procaspase-8/c-FLIPL heterodimer, which results in partial 
cleavage of procaspase-8. Therefore, in this situation, instead of the usual two cleavages, 
only the first one is completed (94). This results in the formation of a p10 fragment and a 
partially active p43-caspase-8 fragment. Interestingly, procaspase-8/c-FLIPL 
heterodimerization occurs with more affinity than procaspase-8 homodimerization, allowing 
a tighter regulation of caspase-8 activation at the DISC (95).  
The p43-caspase-8 fragments have been shown to be unable to initiate death signalling, 
but they can activate themselves and receptor-interacting protein 1 kinase (RIPKs) (90). 
Although this is not enough to initiate apoptosis, this fragment is able to cleave RIPKs. This 
is useful in TNF-α-mediated apoptosis, since c-FLIP can regulate formation of either 
complex IIa, which leads to apoptosis, or complex IIb, which leads to necroptosis (96). When 
caspase-8 activation is inhibited, complex IIb is preferably formed, allowing activation of 
necroptosis due to accumulation of RIPK1 and RIPK3. Nonetheless, with this partial activity 
of p43-caspase-8 molecule, these RIPKs will be cleaved, which impairs activation of 
necroptosis (91).  
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2.2.3.2  Proliferation 
Although the short isoforms of c-FLIP are only related to anti-apoptotic functions, c-
FLIPL has functions beyond regulation of DR-mediated apoptosis, and are related to cell 
survival and cell proliferation. Survival and cell proliferation functions are achieved by p43-
FLIP, which is a fragment obtained from c-FLIPL cleavage at D379 by caspase-8 (90).  
Although caspase-8 is mainly known for its role as an initiator caspase at DR-mediated 
apoptosis, it has been reported to have different functions outside the apoptotic process. 
Caspase-8 can, for instance, initiate NF-κB activation independently of its proteolytic 
activity (97). It can also regulate cell migration due to interaction with integrins, or modulate 
interleukin-1 beta (IL-1β) production upon macrophage activation (98). Since c-FLIP can 
regulate caspase-8 activation at the DISC, it might have an indirect influence on the different 
pathways regulated by DISC. However, more studies are needed to understand the role of c-
FLIP in these different caspase-8 functions. 
The NF-κB protein family is a family of transcription factors, which are responsible for 
inflammation, immune response, protection against apoptosis and differentiation (99). When 
NF-κB is free it can translocate into the nucleus, allowing transcription regulation of anti-
apoptotic and pro-survival proteins (100). It was recently shown that p43-FLIP can interact 
with TNF receptor associated factor 1 and 2 (TRAF1 and TRAF2) and receptor-interacting 
protein 1 (RIP1), promoting activation of NF-κB (90,101). Additionally, another fragment 
obtained from c-FLIP cleavage at D196, p22-FLIP, can interact with IKKγ subunit of the 
IkB kinase (IKK) complex and stimulate activation of this signalling pathway (92). This 
fragment differs from p43-FLIP, since it can be produced without DR stimulation (92,102). 
Besides its functions in DR-induced apoptosis, c-FLIPL also regulates DR-induced NF-κB 
activation (103). This occurs in a concentration-dependent manner. It was shown that high 
amounts of c-FLIPL in the cell, will cause more association of c-FLIPL to the DISC. 
Subsequently, less procaspase-8 will be recruited, forming less procaspase-8/c-FLIPL 
heterodimer. Further, formation of p43-FLIP will be reduced, directly affecting NF-κB 
activation. Nevertheless, studies showed that moderate levels of c-FLIPL are needed for DR-
induction of NF-κB pathway (103–105).  
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2.2.3.3  Cell Cycle 
Studies using c-FLIPL overexpression have suggested that this protein also induces p27 
depletion (106). Additionally, Quintavalle et al. have shown that the p27 mRNA levels were 
also reduced in these cells (106). As referred before, p27 is a CKI that inhibits cyclin E-
CDK2 and cyclin A-CDK2 complexes (figure 2.5) (18). Since, in this case, p27 is decreased, 
it is possible that the concentration of cyclin A and E are increased. Also, p27 was suggested 
to be the molecule responsible for inhibiting G1/S transition (27). Thus, if p27 levels are 
decreased upon c-FLIP overexpression, the G1/S transition will no longer be inhibited, 
which could make this transition process faster. Further, it was shown that Fas/FADD/c-
FLIPL/caspase-8 complex control G1/S transition in epidermal growth factor (EGF)-
stimulated hepatocytes (107). In this study, it is suggested that c-FLIPL expression is induced 
by EGF stimulation, thus increasing the levels of c-FLIP bound to FADD (107). At FADD, 
c-FLIPL associates with procaspase-8, causing cleavage of both proteins and, subsequently, 
higher levels of p43-FLIP (107). Activation of NF-κB by c-FLIPL might also have effects 
on cell cycle progression. Studies have shown that NF-κB has three binding sites in the 
cyclin D1 promoter (108). The sites mainly bind NF-κB1/Rel-A complex, which is increased 
upon mitogen stimulation (93,94). Thus, when mitogens promote cell division, it promotes 
cyclin D1 activation by NF-κB, stimulating G1/S phase transition (figure 2.5). 
The main functions of c-FLIP depend on its cleavage or DED-dependent interactions with 
other proteins. Like many other proteins, c-FLIP is regulated by phosphorylation. However, 
little is known whether this type of PTM plays an important role in its functions. 
Additionally, little is known about how does c-FLIP influence cell population, and if a 
phosphorylation site would be the needed for this mechanism.   
Figure 2.5. c-FLIP interacts with molecules that regulate cell cycle. c-FLIP activates NF-κB, which in turn 
is known to activate cyclin D, stimulating G1/S transition. Additionally, c-FLIP was found to stimulate 
decrease of p27 levels. p27 inhibits cyclin E and A, important regulators of G1/S transition. 
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2.3  Flow cytometric cell proliferation dynamics 
Flow cytometry is a technology that can measure optical and fluorescence characteristics 
of a single cell, as it flows in suspension through a light source. It can analyse the size and 
granularity of cells, as well as their fluorescent features, which is derived from either dyes 
or antibodies (111). When a cell is labelled with a fluorescent probe, the fluorescence that 
the instrument detects is proportional to the amount of probe bound to the cell or cellular 
component. 
This technique is used in several applications, to detect whole cells or cellular 
components. These components can help studying cell proliferation and cell cycle, among 
other mechanisms of the cell (112,113). In this thesis, the focus will be on cell proliferation 
and cell cycle methods. 
 
2.3.1 Carboxyfluorescein succinimidyl ester (CFSE) 
Labelling cells with CFSE is commonly used for cell proliferation studies. To perform 
this label, cells are kept in medium rich in a CFSE precursor molecule, which diffuses into 
the cell. Once inside, it is converted into fluorescent CFSE and binds to proteins, which 
makes the dye unable to pass through the cell membrane. Subsequently, the medium is 
changed to remove extra CFSE precursor molecules. After labelling the cells, the sample is 
analysed at sequential time points using flow cytometry, by measuring the fluorescent 
intensity of the individual cells (figure 2.6) (112). The fluorescent intensity is proportional 
to the amount of label bound to cellular proteins and autofluorescence. Thus, the decrease in 
intensity can either be due to cell division or degradation of cells labelled with CFSE, since 
CFSE is degraded with the protein. Additionally, if a cell dies, CFSE is degraded, so these 
cells do not contribute for the fluorescence (114). After a certain number of cell divisions, 
the fluorescence will become undistinguishable from the autofluorescence. From the 
obtained data it is possible to learn how many cell divisions cells undergo (115). 
 
2.3.2 Click-iT 5-ethynyl-2′-deoxyuridine (EdU) 
Another method to access cell proliferation is measuring DNA synthesis. This was 
initially performed by measuring incorporation of radioactive nucleosides. However, this 
technique was subsequently replaced with antibody-based detection of bromodeoxyuridine 
(BrdU) (116). This method has several limitations and requires a combination of acid, heat, 
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or nucleases treatments to allow the antibody to access the incorporated BrdU residues. Thus, 
new methods were developed over the years to improve detection of S-phase cell cycle 
progression. EdU, which is a nucleotide analogue, is found to be incorporated into DNA via 
click reaction, which enhances the detection of S-phase cell cycle progression (117,118). 
With this method, the DNA is not subjected to harsh treatments, maintaining its helical 
structure, allowing cell cycle staining or labelling of cell surface markers. After EdU 
treatment the cells are fixed, permeabilised and click-labelled. The fluorescence readout can 
be performed using flow cytometry, which gives a histogram with two peaks, one with non-
proliferating cells and another with proliferating cells, which are labelled with EdU. 
Additionally, a staining with propidium iodide (PI) can be performed simultaneously with 
EdU. PI is a fluorescent intercalating agent used to stain cells in flow cytometry to evaluate 
either cell viability or cell cycle (119,120). For cell cycle analysis, the cells must be fixed to 
allow PI to bind to DNA. This dye is stoichiometric, meaning that the binding is proportional 
Figure 2.6. Illustration of CFSE dilution due to cell division. Cell division results in halving of the 
concentration at each division (top). Cells do not divide or proliferate at the same rate, thus we can observe 
different label concentration distribution within the same population (bottom). Two time points are depicted 
by vertical lines, which result in different fluorescence distribution, with t1 yielding only one peak, while t2 
shows a mixture of different generations. 
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to the amount of DNA. The G2 population will fluoresce more brightly, since it has double 
the DNA content, while G1 phase will present the lowest fluorescence. S phase population, 
in its turn, will present a population between G1 and G2 phase, since it will take up the 
fluorescence while the DNA is replicating (119). 
Staining cells with EdU and PI, results in a dot plot with a horseshoe shaped form, which 
tells not only if the cells are proliferating, but also in which cell cycle phase the cells are in. 
From this, we can understand how the cell cycle is influenced under the studied 
circumstances. 
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3 Aims and outline 
c-FLIP is a protein known for its inhibitory role in DR-mediated apoptosis, through 
regulation of procaspase-8 activation at the DISC. Studies have reported that c-FLIP can be 
phosphorylated by PKC at serine 193 (S193) and at serine 227 (S227). However, little is 
known about their role in c-FLIPL functions. It was also suggested that c-FLIP 
overexpression can decrease p27 protein and mRNA levels. With this decrease in both 
mRNA and protein levels, the remaining amount of p27 will not be as effective to inhibit 
cyclin A-CDK2 and cyclin E-CDK2. Unpublished data collected in our lab suggested that a 
serine to alanine mutation at residue 227 of c-FLIPL causes the cells to proliferate less when 
compared to cells transfected with the empty plasmid vector. Furthermore, overexpression 
of c-FLIPL wild type (WT) makes the cells grow faster than cells transfected with an empty 
vector. Therefore, it was hypothesised that either S193 or S227 phosphorylation of c-FLIPL 
could regulate cell cycle and cell population size. To do so, a series of flow cytometric 
studies were performed to infer if c-FLIPL overexpression leads to faster proliferation of 
cells. Further, flow cytometry was used to study differences of cell cycle progression 
between cells transfected with mock, c-FLIPL WT, serine 227 to alanine mutation (S227A) 
and serine 227 to aspartate mutation (S227D). Regulators of G1/S transition were also 
studied to study differences in protein levels between different samples. 
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4 Materials and methods 
4.1 Cell culture  
HeLa and fluorescence ubiquitination cell cycle indicator (Fucci) HeLa cells were 
cultured in a humidiﬁed 5% CO2 atmosphere at 37ºC in Dulbecco's Modified Eagle's 
medium (DMEM) (Sigma-Aldrich) supplemented with 4500 mg/L glucose, 10% fetal calf 
serum (FCS), antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin), 2 mM L-
glutamine and passaged when they were 80 % confluent. 
Fucci HeLa cells express Fucci technology. The Fucci technology allows easy 
determination of G1 and S/G2/M phases of the cell cycle with fluorescent probes: G1-orange 
and S/G2/M-green. The fluorescence is controlled by ubiquitin-mediated proteolysis, which 
degrade the probes in a cell-cycle dependent manner. The green probe is degraded during 
G1 phase, while the orange one is degraded at S/G2/M phases. 
 
4.2 CFSE staining  
8 × 106 HeLa or Fucci HeLa cells were centrifuged and resuspended in 1 mL of Phosphate 
buffered saline (PBS), and 5 µL of CellTrace™ Violet staining solution (Invitrogen) was 
added. Cells were incubated for 20 minutes in a humidified 5% CO2 atmosphere at 37ºC, 
protected from light. 5 mL of DMEM was added to the cells, followed by 5 more minutes of 
incubation. Cell were centrifuged and resuspended in pre-warmed Gibco™ Opti-MEM™ I 
Reduced Serum Media (OptiMEM) (GibcoBRL) for transfections. 
 
4.3 Transfections 
For transfections, 8 × 106 Fucci HeLa and HeLa were centrifuged and resuspended in 1.6 
and 2 ml of OptiMEM, respectively, and 0.4 mL was added to electroporation cuvettes 
(BTX) with pre-added 10 µg of plasmid DNA. Cells were subjected to a single electric pulse 
(220 V, 975 µF) in 0.4 cm electroporation cuvettes using a Bio-Rad Gene Pulser 
electroporator, followed by dilution in DMEM with 10% FCS, antibiotics and L-glutamine. 
Cells were counted, followed by plating in DMEM and culturing in a humidiﬁed 5% CO2 
atmosphere at 37ºC. 
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4.4 Cell proliferation assay 
 3 × 104 HeLa or Fucci HeLa cells transfected with empty vector mock, c-FLIPL-WT, c-
FLIPL-S227A, c-FLIPL-S227D or c-FLIPS plasmids were plated in 6-well plates, in 
duplicates, for 4 day-experiments. Every 24 hour, one of the samples was used for cell 
counting using a hemocytometer, followed by lysis in laemmli buffer (62.5 mM TRIS-HCl 
pH 6.8, 1 % SDS, 10 % glycerol, 0.005 % bromophenol blue and 1 % beta-mercaptoethanol) 
and heated for 5 to 10 minutes at 98ºC. Each lysate protein was loaded and resolved by 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The other sample 
was fixed with 50 µL of Fixation/Permeabilization solution (BD Biosciences) for 20 
minutes, on ice, and washed with 100 µL of BD Perm/Wash Buffer (BD Biosciences), inside 
an eppendorf tube. Cells were centrifuged and resuspended in 250 µL of BD Perm/Wash 
Buffer and run by flow cytometry, on BD LSR II (BD Biosciences). Data analysis was 
performed using FCS Express 6 Flow Cytometry software (De Novo Software). 
  
4.5 SDS-PAGE and western blotting.  
For western blot analysis, cells were lysed in laemmli buffer and heated for 5 to 10 
minutes at 98ºC. Each lysate protein was loaded and resolved by SDS-PAGE (10-12%) with 
a buffer containing 250 mM glycine, 25 mM TRIS-base and 0.1 % SDS. The gels were run 
for 30 minutes using 80 V, followed by 90 minutes at 120 V. The resolved samples were 
then transferred to nitrocellulose membrane using wet transfer apparatus for 1 hour with 400 
mA. The transfer buffer used contained 192 mM glycine, 24 mM TRIS-base and 20 % 
methanol. Membranes were blocked with 5% milk in PBS and then incubated with the 
desired primary antibody (table 1), overnight at 4ºC. On the next day, the membranes were 
washed three times for 7 minutes, and incubated with the appropriate secondary antibody for 
1 hour at room temperature. Then, the membranres were washed three times for 10 minutes. 
Finally, the membranes were exposed with 1:10 SuperSignal™ West Femto Maximum 
Sensitivity Substrate : SuperSignal™ West Pico Chemiluminescent Substrate 
(ThermoFisher Scientific). 
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4.6 EdU assay 
3 × 104 HeLa cells transfected with empty vector mock, c-FLIPL-WT, c-FLIPL-S227A, c-
FLIPL-S227D or c-FLIPS plasmids were plated in 6-well plates, for a 4 days experiment. 
Every 48 hours, 10 µM of EdU (Invitrogen) was added to 2 mL of culture medium, and 
incubated in a humidiﬁed 5% CO2 atmosphere at 37ºC, for 2 hours. Subsequently, the cells 
were harvested and fixed using 50 µL of Click-iT fixative (Invitrogen), for 15 minutes at 
room temperature, protected from light. This was followed by addition of 100 µL of Click-
iT saponin-based permeabilisation and wash reagent (Invitrogen). Next, 250 µL of Click-
iT reaction cocktail (Invitrogen) was added to each sample, followed by 30 minutes 
incubation at room temperature, protected from light. The samples were washed before 
staining with 250 µL of FxCycle PI/RNase Staining Solution (Invitrogen), for 15 minutes. 
Finally, samples were run on BD LSR II and analysed by FCS Express 6 Flow 
Cytometry software. 
 
4.7 Fucci cell cycle 
3 × 104 Fucci HeLa cells transfected with empty vector mock, c-FLIPL-WT, c-FLIPL-
S227A or c-FLIPL-S227D plasmids were plated in 6-well plates, for a 2 day-experiment. 
Every 24 hours, samples were harvested and fixed with 50 µL of Fixation/Permeabilisation 
solution for 20 minutes, on ice, and washed with 100 µL of BD Perm/Wash Buffer, inside 
an eppendorf tube. Cells were centrifuged and resuspended in 250 µL of BD Perm/Wash 
Buffer and run by flow cytometry, on BD LSR II. Data analysis was performed using FCS 
Express 6 Flow Cytometry software. 
 
Primary Antibody Company 
Secondary 
Antibody 
Company 
FLIP (7F10) Enzo Life Sciences, USA IgG1 SouthernBiotech 
FLAG Cell Signalling Technology, USA Rabbit Promega, USA 
HSC70 Enzo Life Sciences, USA Rat GE Healthcare, UK 
Cyclin E Cell Signalling Technology, USA IgG1 SouthernBiotech 
p27 Santa Cruz Biotechnology, USA Rabbit Promega, USA 
PCNA ChromoTek, Germany Rat GE Healthcare, UK 
 Table 4.1 List of diluted primary antibodies and respective secondary antibodies used for WB 
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4.8 Double thymidine block 
3 × 104 Fucci HeLa cells transfected with empty vector mock or c-FLIPL-WT plasmids 
were plated in 6-well plates. After 12 hours, cells were washed with PBS, DMEM was added 
with 2 mM of thymidine for 18 hours. To remove first thymidine block, cells were washed 
with PBS and fresh DMEM was added for 9 hours. Cells were, once again, washed with 
PBS, and DMEM with 2 mM of thymidine was added for the second thymidine block. After 
17 hours, cells were released from block by one wash of PBS and addition of fresh DMEM. 
Cells were harvested at 0, 2, 4, 6, 10 and 12 hours after second thymidine block release and 
fixed with 50 µL of Fixation/Permeabilization solution for 20 minutes, on ice, and washed 
with 100 µL of BD Perm/Wash Buffer, inside an eppendorf tube. Cells were centrifuged and 
resuspended in 250 µL of BD Perm/Wash Buffer and run by flow cytometry, on BD LSR II. 
Data analysis was performed using FCS Express 6 Flow Cytometry software. 
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5 Results 
5.1 S227A c-FLIPL lead to slower cell proliferation 
Previous unpublished data from the lab (figure 5.1), shows differences in cell population 
size upon overexpression of various c-FLIPL plasmids. This figure shows us transfection of 
that the c-FLIP plasmid with phosphodeficient mutation (S227A), causes the cells to 
proliferate less when compared to cells transfected with the empty vector (mock). 
Additionally, overexpression of c-FLIPL WT makes the cells grow faster than those 
transfected with mock. This results suggest that c-FLIPL has an impact on cell proliferation. 
For the continuation of the project, both HeLa and Fucci HeLa cells were used and 
transfected with mock, WT, S227A and S227D plasmids. The cells were harvested 24h, 48h, 
72h and 96h after transfection, and counted with a hemocytometer. After 24 hours of 
transfection, the number of cells was on average 0.4 × 105 cells (figure 5.2). After four days, 
it is noticeable that S227A has on average less cells (2.4 × 105 cells) than mock, WT and 
S227D transfected cells (3.3 × 105 cells). The same results were obtained using Fucci HeLa 
cells, which started with an average of 0.35 × 105 cells. At the fourth day, S227A cells had 
a smaller cell population size (2.6 × 105 cells) than mock, WT and S227D (3.9 × 105 cells). 
The results obtained from both HeLa and Fucci HeLa cells were similar to the previous 
experiments from the lab (figure 5.1). However, no significant changes between the cells 
transfected with mock, WT and S227D plasmids were found.  
Figure 5.1 Serine to alanine mutation at 227 site cause cells to proliferate slower than WT. HeLa cells 
were transfected with different plasmids, and counted in a 4 day-experiment. Overexpression of c-FLIPL 227A 
and c-FLIPl  193/227AA lead to slower cell proliferation, while the 193A shows similar number count as WT. 
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To further investigate how c-FLIPL and its phosphorylation site in S227 affect cell 
proliferation, the cells were stained with CFSE, followed by transfection with mock, WT, 
S227A and S227D. Once again, both HeLa and Fucci HeLa cells were used and harvested 
24, 48, 72 and 96 hours after transfection, and they were fixed and analysed by flow 
cytometry. CFSE staining makes cells fluorescent, which will get weaker every time the 
cells divide. The analysis gives a histogram (figure 5.3), which contains information related 
how many times cells have divided and the percentage of cells per division. As cells divide, 
it is expected that the fluorescence of the population decreases, causing a shift to the left. 
On the first day, most HeLa cells had undergone 2 divisions (figure 5.4). From the data, 
it is noticeable that the cells transfected with S227A had a higher percentage at the 
population that divided only once, when compared to the others. From the cells that divided 
two times, there were also less cells in the S227A-transfected cells compared to mock, WT 
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Figure 5.3 Representation of a histogram created from the data obtained by flow cytometry. Alexa fluor 
405-A axis represents the intensity of fluorescence detected by the instrument. As the cells divide, the intensity 
decreases, causing a shift of the population to the left of the axis. Data was obtained from BD LSR II and 
analysed using FCS Express 6 Plus. 
Figure 5.2 Serine to alanine mutation at 227 site causes cells to grow slower than mock, WT and S227D. 
HeLa and Fucci HeLa cells were transfected with different plasmids, and counted in a 4 days experiment. 
Overexpression of c-FLIPL S227A lead to slower cell proliferation when compared to Mock, WT and S227D. 
Cells were counted using a hemocytometer. Two experimental replicates were made. 
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and S227D. Therefore, from the first day, it seems that the phosphodeficient S227A mutant 
of c-FLIPL causes the cells divide slower. This delayed profile of S227A cells is maintained 
along the following days. However, no obvious differences were found between the mock, 
WT and S227D cells (figure 5.4). When experimenting with Fucci HeLa cells, the same 
profile of cells was found (figure 5.5). Cells transfected with S227A plasmids show also a 
delayed profile when compared to the other cells, from day one to day four. However, it 
seems that mock Fucci cells divide faster than the WT and S227D cells, which was not seen 
in HeLa cells (figure 5.5).  
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5.2 c-FLIP S227A-transfection causes accumulation of cells at G1 phase 
From the previous results, it was found that the phosphodeficient c-FLIPL might affect 
cell division, causing them to proliferate slower when compared to other transfected cells. 
Thus, to further investigate this, Fucci cells were used to study cell cycle progression. For 
this purpose, Fucci cells were transfected with mock, WT, S227A and S227D plasmids, and 
plated. Cells were then harvested after 24 and 48 hours after transfections, fixed and analysed 
Figure 5.4 S227A cells proliferate slower than mock, WT and D227. HeLa cells were transfected with 
mock, WT, S227A and S227D to study their effects on proliferation. It was found that S227A proliferates 
slower than mock, WT and S227D. Days represent time after transfection at which the cells were harvested. 
Data was obtained from BD LSR II and analysed using FCS Express 6 Plus. Two experimental replicates 
were made. 
 
26 
 
D a y  1
D iv is io n s
P
e
r
c
e
n
ta
g
e
0 1 2 3 4 5 6 7
0
2 0
4 0
6 0
8 0
1 0 0
M o c k
W T
S 2 2 7 A
S 2 2 7 D
D a y  2
D iv is io n s
P
e
r
c
e
n
ta
g
e
0 1 2 3 4 5 6 7
0
2 0
4 0
6 0
8 0
M o c k
W T
S 2 2 7 A
S 2 2 7 D
D a y  3
D iv is io n s
P
e
r
c
e
n
ta
g
e
0 1 2 3 4 5 6 7
0
2 0
4 0
6 0
8 0
M o c k
W T
S 2 2 7 A
S 2 2 7 D
D a y  4
D iv is io n s
P
e
r
c
e
n
ta
g
e
0 1 2 3 4 5 6 7
0
2 0
4 0
6 0
8 0
M o c k
W T
S 2 2 7 A
S 2 2 7 D
using flow cytometry. Fucci technology allows easy determination of the different cell cycle 
phases using constructs that give orange colour to G1 phase nuclei, and green colour to 
S/G2/M phases nuclei. At an early stage of G1 phase, the cells are not labelled. When 
analysing Fucci HeLa cells with flow cytometry, a dot plot (figure 5.6) can be obtained. The 
cells located in the lower left quadrant are those which do not have fluorescence, 
corresponding at an early G1 phase. The G1 phase is located at the top left quadrant, while 
G2/M phase is at the lower right side of the dot plot. Lastly, the top right quadrant represents 
cells which are labelled with green and orange colour simultaneously, which were 
considered to be in S phase (figure 5.6). 
From figure 5.7, it is evident that after 24 hours of transfection, mock-transfected cells 
have most cells committed to division, with 40.56% of cells at the S phase and 20.04% at 
G2/M phase. On the second day, most mock-transfected cells are preparing for mitosis, with 
7.99% at an early G1 phase and 40.62% at G1 phase. Similarly, most cells transfected with 
WT plasmid are committing to divide, with 39.47% of cells at S phase and 17.79% at G2/M. 
Figure 5.5 S227A cells are slower proliferating than mock, WT and D227. Fucci HeLa cells were 
transfected with mock, WT, S227A and D227 to study their effects on proliferation. It was found that S227A 
proliferates slower than mock, WT and D227. Furthermore, it seems that mock cells are growing faster than 
WT and D227.  Days represent time after transfection at which the cells were harvested. Data was obtained 
from BD™ LSR II and analysed using FCS Express 6 Plus. Two experimental replicates were made. 
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On the second day, these WT cells, also have a cell cycle profile similar to the mock cells. 
However, some differences were found with S227D cells, where there was a lower 
percentage of cells at G2/M phase (17.05%) on day 1 when compared to mock and WT. 
However, the percentage of S227D cells at early G1 and G1 phase was 45.75%, which was 
higher than in mock (39.41%) and WT (42.74%). This difference is still noticeable on the 
second day, where S227D cells have a higher percentage of cells prepared to divide, when 
compared with both mock and WT. This suggests that cells overexpressing c-FLIPL with a 
phosphomimicking mutation could be dividing faster. Moreover, S227A cells show an 
increased population in an early G1 phase at day 1 (13.84%), while other transfected cells 
had between 5 to 8% of cells in that phase. This accumulation of G1 population for S227A 
cells remained on the second day, having reached 20.90% of cells in early G1 phase, while 
other cells reached only 8 to 12%. Additionally, it seems that the S227A mutation slows 
entry into the S phase, since there were only 26.73% of cells in this 17.95%phase, while 
mock, WT and S227D had more than 30% of cells in S-phase.  
Similar results could be obtained using HeLa cells. However, these cells need to be treated 
with EdU for 2 hours, followed by harvesting and Click-iT reaction. Further, the cells were 
stained with FxCycle™ PI/RNase staining solution, just before being analysed by flow 
cytometry. However, when this staining was performed in the transfected samples, we did 
not obtain the expected profile when analysing by flow cytometry. When the staining works 
as it should, the profile should be similar to the figure 5.8A. From that profile, we can obtain 
the percentage of cells in G1, S and G2 phase, because cells have different fluorescent 
Figure 5.6 Representation of a dot plot obtained from Fucci HeLa cells for cell cycle studies. FITC-A 
axis represents the intensity of green fluorescent detected, while PE-A axis represents intensity of the orange 
colour. The percentages of cells per quadrant are shown. The lower left quadrant represents early G1 phase 
cells, while the top left cells in G1 phase. The top right quadrant contains cells in S phase, while lower right 
contains cells from G2/M phase. Data was obtained from BD LSR Fortessa and analysed using FCS Express 
6 Plus. 
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intensities of EdU and PI dependent on the cell cycle phase. However, when we tried the 
staining using our transfected samples, we obtained the profile shown figure 5.8B, which 
was not expected and does not allow us to analyse the cell cycle of HeLa cells. 
 
5.3 c-FLIP WT-transfected cells seem to progress through cell cycle 
faster than mock 
Although some differences between the transfected cells were found with the previous 
experiment, it was not sufficient to pinpoint if the cells overexpressing c-FLIP WT and 
mutants were faster or slower to divide than the mock cells. Thus, an experiment where Fucci 
HeLa cells transfected with either mock or WT plasmids were synchronised, was performed. 
These cells were synchronised using double thymidine block, which blocked the cells 
Day 1 Day 2 
Mock 
WT 
S227A 
S227D 
5 .0 5 %   E a r ly  G 1
3 4 .3 6 %   G 1
4 0 .5 6 %   S
2 0 .0 4 %   G 2 /M
7 .9 9 %   E a r ly  G 1
4 0 .6 2 %   G 1
3 0 .0 7 %   S
2 1 .3 3 %   G 2 /M
7 .2 4 %   E a r ly  G 1
3 5 .5 0 %   G 1
3 9 .4 7 %   S
1 7 .7 9 %   G 2 /M
1 1 .6 7 %   E a r ly  G 1
3 6 .4 6 %   G 1
3 1 .4 7 %   S
2 0 .4 0 %   G 2 /M
1 3 .8 4 %   E a r ly  G 1
3 6 .5 4 %   G 1
2 9 .0 8 %   S
2 0 .5 4 %   G 2 /M
2 0 .9 0 %   E a r ly  G 1
3 5 .9 4 %   G 1
2 6 .7 3 %   S
1 6 .4 3 %   G 2 /M
8 .8 4 %   E a r ly  G 1
3 6 .9 1 %   G 1
3 7 .2 1 %   S
1 7 .0 5 %   G 2 /M
5 .5 7 %   E a r ly  G 1
3 8 .5 0 %   G 1
3 2 .9 0 %   S
2 3 .0 3 %   G 2 /M
Figure 5.7 S227A shows an increased population at an early G1 and G1 phase when compared to mock, 
WT and S227D. Fucci HeLa cells were transfected with mock, WT, S227A and S227D to study their effects 
on cell cycle progression. S227A has an accumulating population at early G1 and G1 phases.  S227D seems 
to be progressing through the cell cycle faster than mock and WT. Days represent the time after transfection 
that the cells were harvested. Data was obtained from BD LSR Fortessa and analysed using FCS Express 6 
Plus. Two experimental replicates were made. 
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throughout the S phase, and they were harvested 0, 2, 4, 6, 10 and 12 hours after being 
released. The cells were then fixed and analysed by flow cytometry. Cells that were not 
synchronised were used as control of the synchronisation method. Figure 5.9 shows that 
thymidine block worked, since the profile of unsynchronised and synchronised cells is 
different. However, the first two time points did not show the expected profile, since 
thymidine block arrest cells at the G1/S phase, and these samples show a significant 
percentage of cells at G2/M (figure 5.9). After 4 hours, the obtained profiles start to be as 
expected, because most cells are in G2/M phase. At 6 hours after release, there was an 
increase of 9.57% in mock and 6.97% in WT, in G2/M population. Differences in the cell  
cycle profile started to be noticeable at the 10th hour after release, when most of the cells 
reach the G1 phase. Mock cells, had an increase of 19.55% and 39.33% in early G1 and G1 
populations, respectively. WT, in their turn, had an increase of 14.3% in early G1 phase, 
while G1 phase the increase reached 41%. This suggests a difference of cell cycle 
progression between WT and mock, which is bigger after 12 hours. When we compared the 
population in early G1 phase, it was found that WT cells had only 14.60%, a lower 
percentage than mock (24.86%). However, when we looked at the G1 phase, the percentages 
of WT were higher than mock 7.94%. This could suggest that WT cells are dividing faster 
than mock.  
 
 
 
A B 
Figure 5.8 Representation of a dot plot obtained from HeLa cells for cell cycle studies. PE-A axis 
represents the intensity of PI, while Alexa fluor 405-A axis represents intensity of fluorescence obtained from 
Click-iT reaction. The percentages of cells per region are shown, as well as which cell cycle phase does each 
region represent. Data was obtained from BD LSR II and analysed using FCS Express 6 Plus. 
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3 .7 5 %   E a r ly  G 1
4 4 .7 6 %   G 1
3 2 .5 0 %   S
1 8 .9 8 %   G 2 /M
8 .8 4 %   E a r ly  G 1
4 3 .0 1 %   G 1
2 8 .0 4 %   S
2 0 .1 2 %   G 2 /M
2 .7 4 %   E a r ly  G 1
6 .0 3 %   G 1
1 0 .0 8 %   S
8 1 .1 5 %   G 2 /M
2 .8 5 %   E a r ly  G 1
7 .6 8 %   G 1
1 3 .1 6 %   S
7 6 .3 1 %   G 2 /M
2 .9 3 %   E a r ly  G 1
5 .5 8 %   G 1
6 .2 0 %   S
8 5 .2 9 %   G 2 /M
4 .0 1 %   E a r ly  G 1
6 .2 4 %   G 1
9 .8 0 %   S
7 9 .9 5 %   G 2 /M
6 .6 3 %   E a r ly  G 1
1 1 .6 0 %   G 1
9 .1 9 %   S
7 2 .5 8 %   G 2 /M
9 .7 6 %   E a r ly  G 1
1 3 .8 8 %   G 1
9 .4 5 %   S
6 6 .9 1 %   G 2 /M
8 .9 7 %   E a r ly  G 1
4 .3 7 %   G 1
4 .5 1 %   S
8 2 .1 5 %   G 2 /M
1 1 .0 5 %   E a r ly  G 1
9 .4 8 %   G 1
5 .5 9 %   S
7 3 .8 8 %   G 2 /M
2 8 .5 2 %   E a r ly  G 1
4 3 .7 0 %   G 1
4 .0 7 %   S
2 3 .7 1 %   G 2 /M
2 6 .3 6 %   E a r ly  G 1
5 0 .4 8 %   G 1
4 .1 6 %   S
1 9 .0 0 %   G 2 /M
2 4 .8 6 %   E a r ly  G 1
6 6 .1 9 %   G 1
3 .3 5 %   S
5 .6 0 %   G 2 /M
1 4 .6 0 %   E a r ly  G 1
7 4 .1 3 %   G 1
5 .0 1 %   S
6 .2 6 %   G 2 /M
Mock WT 
Unsynchronised 
12h 
6h 
10h 
4h 
2h 
0h 
Figure 5.9 WT progress faster through cell cycle. Fucci HeLa cells were transfected with mock and WT, 
followed by thymidine block, to study which transfected population was faster progressing through the cell 
cycle. WT seems to be progressing through the cell cycle faster than mock. Hours represent the time which 
the cells were harvested after being released from thymidine block. Data was obtained from BD LSR Fortessa 
and analysed using FCS Express 6 Plus. One experimental replicate was made. 
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5.4 S227A-transfected cells have decreased levels of cyclin E 
It was previously referred that c-FLIPL overexpression could influence the cell cycle, 
more specifically at the G1/S transition. Thus, from the cells plated for CFSE experiments, 
one of the duplicates was collected for western blotting to study how cell cycle regulators 
levels are affected by mock, WT, S227A and S227D transfections, along the four days of 
experiments. First, we blotted for c-FLIPL to study transfection efficiency. From the blots, 
three bands were found: the lower one represents p43-FLIP, which is a cleaved form of c-
FLIPL; the middle band is c-FLIPL, while the top is the FLAG-tagged c-FLIPL, produced 
from the plasmid that was transfected (figure 5.10). The blots confirmed that there was 
overexpression of c-FLIPL throughout the four days, although S227A cells had less amount 
of c-FLIPL than WT and S227D. Cyclin E, which is a major regulator of G1/S transition, 
was also studied. From the first day, it seems that the phosphomimicking mutation stimulates 
cyclin E expression, while the phosphodeficient mutation causes a decrease of it. On the 
second day, it was found that both WT and S227D lead to more of cyclin E when compared 
to mock and S227A. This was also found on the third day, although the mock sample showed 
more cyclin E than the others. This could explain why cells overexpressing WT and S227D 
grow faster than S227A cells (figure 5.10). p27, which is another important regulator of G1/S 
transition, was also studied. Differences were only found on the first and fourth day after 
transfection. After 24 hours, it was found that WT and S227D cells had more p27 than the 
others, while on the fourth day this was found in both mock and S227D. Both results are not 
as expected, since overexpression of c-FLIPL leads to p27 depletion. Proliferating cell 
nuclear antigen (PCNA), an important component of the nucleic acid metabolism and cell 
cycle regulation, and used as proliferative marker, was also studied. From the first and 
second day, it was found that S227A cells had weaker bands when compared to the other 
transfected cells. No differences were found on the third day, and on the last day it seems 
that the WT transfected cells had less amount of PCNA. Heat shock 70 kDa protein 8 
(Hsc70) was the protein used as a loading control. No significant differences on the loading 
were found, except for the fourth day, which seemed to have had less amount of S227D 
loaded, which could be due to bad blotting. 
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Fucci HeLa cells samples were also used for western blotting. Once again, when blotted 
with anti-c-FLIP antibody it was found that there was overexpression of WT, S227A and 
S227D (figure 5.11). However, mock samples from the second, third and fourth day showed 
to have c-FLIP expression comparable to the overexpressed samples, which should not 
occur, because mock is an empty vector that cannot overexpress c-FLIPL. While studying 
cyclin E, it was found that, on the first day, S227D had stronger band when compared to 
other, with mock sample having the weaker band. On the following day, the WT sample had 
the weaker band, while on the fourth day no significant differences were found, although 
mock transfected cells appear to have a stronger band than others (figure 5.11). With PCNA, 
it was found that, on the first and second day, S227D sample had a stronger band than the 
others, although on the second day S227A had a band with similar intensity than S227D. 
However, on the fourth day, S227A showed a much weaker band than the others, which 
would suggest less proliferation of these cells. Again, Hsc70 was used as a loading control, 
which showed differences in the loading of the third and fourth day, which higher amount 
of mock and WT samples.  
 
 
 
 
Day 1 Day 2 Day 3 Day 4 
c-FLIPL    - 
Cyclin E - 
p27          - 
PCNA    - 
Hsc70    - 
Figure 5.10 Cyclin E levels are lower in S227A. c-FLIPL was shown to be overexpressed in WT, S227A and 
S227D samples. Cyclin E shows low levels in S227A, and higher levels in D227. p27 and PCNA blots do not 
show a consistent profile across the different days. Hsc70 was used as a loading control. HeLa cells were 
transfected with mock, WT, S227A and S227D. After, they were harvested at different time points after 
transfection, run in a 10-12 % SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane 
was incubated with the desired primary and secondary antibodies, followed by development with enhanced 
chemiluminescence (ECL) western blotting substrate. Two experimental replicates were made.  
p43-FLIP - 
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Day 1 Day 2 Day 3 Day 4 
c-FLIPL  - 
Cyclin E  - 
PCNA     - 
Hsc70      - 
Figure 5.11 c-FLIPL was shown to be overexpressed in WT, S227A and S227D samples. Cyclin E shows high 
levels in S227D, however other samples do not show consistent band intensity upon different days. PCNA 
blots also do not show a consistent profile across the different days. Hsc70 was used as a loading control. 
Fucci HeLa cells were transfected with mock, WT, S227A and S227D. After, they were harvested at different 
time points after transfection, run in a 10-12 % SDS-PAGE gel and transferred to a nitrocellulose membrane. 
The membrane was incubated with the desired primary and secondary antibodies, followed by development 
with ECL western blotting substrate. Two experimental replicates were made. 
p43-FLIP - 
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6 Discussion 
Since the discovery of c-FLIP, most studies were concerning the anti-apoptotic roles of 
this protein. These roles were found to be more related to the short form of c-FLIP, while c-
FLIPL could also have pro-apoptotic roles. Furthermore, some reports started to show 
evidence that the long form of this protein could have roles in cell proliferation and cell-
cycle progression (107). Moreover, among the different ways to control c-FLIP, previous 
unpublished work from our laboratory suggested that phosphorylation at serine 227 could 
have an effect in cell proliferation, while c-FLIPL was being overexpressed. Thus, we started 
by studying cell population while overexpressing c-FLIPL WT, S227A or S227D. These 
results showed, for both HeLa and Fucci HeLa cells, that S227A cells had fewer cells after 
four days of experiment, when compared to mock, WT and S227D. This suggests that the 
serine to alanine mutation, which cannot be phosphorylated due to lack of a hydroxyl group, 
affects the cells capacity to proliferate as fast as the others. However, the number of cells 
obtained from the mock transfected cells were higher than expected, since unpublished data 
from our lab had shown that mock cells proliferate slower than WT and S227D. 
Additionally, we studied the proliferative behaviour of cells through the CFSE method, 
which allowed us to understand how fast cells were proliferating (115). We found that cells 
overexpressing phosphodeficient c-FLIPL proliferate slower, when compared to the other 
cells. Overall, a bigger population of S227A cells was found to undergo less one division 
than mock, WT and S227D. Once again, during these experiments we saw the mock 
population to grow at the same rate as WT and S227D, or even faster, in the case of Fucci 
HeLa cells. This could occur because of problems with the plasmid used for transfection, 
which might be stimulating some cellular mechanism, causing cell to proliferate faster than 
expected. Based on previous experiments, we expected both WT and S227D to be the fastest 
growing cells, and S227A to be the slowest ones. These results confirm S227A mutation 
affects cell proliferation. Moreover, this slower proliferation profile found through CFSE 
method could explain why cell counts were smaller in the previous experiment.  
Western blot was also performed to study the expression of PCNA, a proliferative marker. 
Weaker bands in S227A samples from HeLa cells were found, which was expected, since 
this cells have been shown to be the ones with slower proliferation. Further, in samples from 
Fucci HeLa cells, we found stronger bands of PCNA in S227D samples, which was expected 
due to faster proliferation. However, mock and WT showed weaker bands than S227D, even 
35 
 
though in cell counting experiments and CFSE method they showed to behave similarly to 
S227D cells. Additionally, the results obtained from PCNA blots, were not entirely 
consistent with the observations made using proliferative methods. 
The G1/S transition of the cell cycle is crucial for the cells, since an “all-or-none switch” 
is created, which forces the cells to divide, only stopping if errors occur along the division 
mechanism (121). Thus, this transition can control the rate the cells are proliferating at. To 
further understand why these S227A transfected cells grow slower than the others, we 
studied the cell cycle profile of these cells. We stained HeLa cells with EdU and PI, however, 
the results were not as expected, since we could not differentiate proliferating cells from the 
non-proliferating. From these results, it would seem that either the cells did not incorporate 
EdU, or they incorporated it, but the Click-iT® reaction was not successful. Nevertheless, 
using HeLa cells stably expressing Fucci, we were able to follow cell division. Additionally, 
using flow cytometry analysis, it was possible to calculate the percentage of cells within 
each cell cycle phase (122,123). From this, we found that cells overexpressing 
phosphodeficient c-FLIPL had much higher percentage of cells at early G1 phase, when 
compared to the other transfected cells. These differences were even bigger on second day 
after the transfection, which suggests that the mutation is affecting the normal progression 
of cell cycle and, consequently, making them proliferate slower. Overexpression of c-FLIPL 
caused a decrease of p27 protein levels, which is a known CKI that inhibits cyclin E-CDK2 
(106). Moreover, p27 protein was suggested to inhibit G1/S transition (27). Thus, S227A 
cells might be accumulated at an early G1 phase, because the phosphodeficient mutation 
makes c-FLIPL unable to stimulate a p27 decrease, and so the cells do not progress to S phase 
as easily. Additionally, we found a small difference between S227D, WT and mock cells, 
which suggests that S227D cells were progressing faster throughout the cell cycle. However, 
when looking at the levels of p27 via western blot in HeLa cells, the differences found were 
not the expected, since WT and S227D had higher levels of p27 when compared to mock 
and S227A. Since cyclin E is one of the targets of p27 protein, we searched if its levels were 
affected in WT and S227D cells. From HeLa cells samples, we found evidence that cyclin E 
can be stimulated by c-FLIPL S227D and WT overexpression, even though the intensity of 
p27 bands were either stronger or similar to mock samples. This could suggest that the levels 
of cyclin E were enough to overcome p27 inhibition, without the need of decreasing p27 
levels. It was shown that cyclin E overexpression could shorten G1 phase, by premature 
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activation of cyclin E-CDK2 complex (9). Thus, it is possible that these higher levels of 
cyclin E found in S227D and WT samples are the reason why these cells progress faster to 
S phase, making them grow faster than S227A transfected cells. 
Although using unsynchronised Fucci HeLa cells to study cell cycle profile showed us 
that there was an accumulating number of cells at early G1 phase in S227A samples, 
differences between the other samples were hard to identify. Therefore, a preliminary 
experiment using synchronised Fucci HeLa cells was also performed. This was done to 
verify if we could overcome the problem of understanding if one cell population was being 
faster or slower than the other. This way, we could analyse how the cells progress through 
the cell cycle phases, while starting from the same phase. Samples from 0 and 2 hours after 
release showed a high percentage of cells at G2/M, which is not correct because double 
thymidine block arrest cells at G1/S transition. It is possible that one of the two blocking 
step was not successful, allowing cells to progress until G2/M phase. However, after 4 hours 
the profile starts to be as expected (124), followed by an increase of G2/M population at 6 
hours after release. This preliminary result showed at 10 hours a small difference between 
the WT and mock, in which WT had a higher percentage of cells at G1 phase, which was 
even more noticeable at 12 hours after thymidine release. This could suggest that WT cells 
were dividing faster than the mock cells. Nevertheless, further trials need to be done, 
including samples of cells overexpressing c-FLIPL mutants.  
From the data we collected, it would seem that c-FLIPL has indeed a role in cell 
proliferation while being overexpressed. Furthermore, we found that throughout the four 
days of experiments, cyclin E levels of WT and S227D cells were higher than S227A cells, 
even though a decrease in p27 levels was not found. This can suggest that c-FLIPL 
overexpression stimulates G1/S transition without changing p27 protein levels. We found 
that, while overexpressing c-FLIPL, a big amount of this protein was cleaved into p43-FLIP 
fragment. Reports have shown that c-FLIPL could interact with NF-κB by this fragment 
(90,101). Additionally, p22-FLIP fragment was found to be interacting and activating IKK 
complex (92,102). Also, studies have shown that inactivating NF-κB can cause delay in G1/S 
transition (125). Thus, it could also be possible that the overexpression will cause an increase 
in interaction of c-FLIPL fragments with NF-κB and IKK complex, which would lead to 
faster G1/S transition and, subsequently, increased cell proliferation. However, studying c-
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FLIPL cleavage into p22-FLIP and p43-FLIP, as well as interaction studies with NF-κB and 
IIK complex are needed to further investigate this. 
How c-FLIPL overexpression affects the cell population can be important for tumour 
growth. It was shown that this protein is frequently upregulated in some human tumours 
(126,127). Further, it was suggested that it could affect cell cycle progression and increase 
cell proliferation in carcinogenesis (107,128). The data we collected is in agreement with 
these suggestions, showing that overexpression of c-FLIPL affects cell proliferation and cell 
cycle progression. Further, our data suggests that this is controlled by S227 phosphorylation. 
Due to its anti-apoptotic role, c-FLIP has also been studied as a target for cancer therapy, 
with different approaches being tested (129–131). Studies have shown that targeting c-FLIP 
could represent an effective anti-tumour therapy. Our findings can further support this claim, 
since targeting c-FLIPL can also reduce cell proliferation.  
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7 Concluding remarks and future perspectives 
c-FLIPL was first identified as having only an anti-apoptotic role, though now it is known 
that it can control cell fate by affecting different cell mechanisms. Some groups have 
suggested that c-FLIPL can have a role in controlling cell proliferation and cell cycle, even 
though the exact mechanism by which c-FLIP controls these processes is still unknown. Our 
study shows that overexpression of c-FLIPL can indeed affect cell proliferation, and indicate 
that phosphorylation at S227 is important for it. Further, our data regarding the cell cycle 
showed that the phosphodeficient mutation at 227 lead to accumulation of cells across G1 
phase. Nonetheless, further repetitions of these experiments need to be performed due to 
unexpected results obtained from the mock transfected cells. After these repeats, we might 
be able to infer if overexpression of WT c-FLIPL grows indeed faster than the control cells, 
and which are the differences found at the cell cycle progression. Furthermore, 
synchronising cells need to be performed in order to further study cell cycle progression. 
From this, we can infer about the time one population needs to complete the cell cycle. We 
will also repeat the EdU protocol, which will give us further information about the cell cycle 
progression in HeLa cells. The blots will also be repeated due to inconsistent results that we 
have obtained during this experiments. Cells expressing fluorescent-tagged cyclin E, 
fluorescent-tagged cyclin A or fluorescent-tagged p27 proteins transfected with mock, WT, 
S227A and S227D will be used and analysed using flow cytometry. From these results, since 
the fluorescent is proportional to the levels of protein in the cell, we can search for 
differences in protein levels in the different transfected cells. We are also planning on 
understanding which is the enzyme responsible for phosphorylating c-FLIPL at S227. Chick 
chorioallantoic membrane assay might also be used as an in vivo model to study the effects 
of c-FLIPL overexpression on cell population size.  
c-FLIPL upregulation in some human tumours, added to the fact that it affects cell 
proliferation while overexpressed, makes it a promising target for cancer therapy. However, 
its resemblance to caspase-8 makes c-FLIPL targeting a bigger challenge. Thus, further 
studies need to be done in order to target c-FLIPL without affecting caspase-8 levels. 
Therefore, further study S227 phosphorylation as the regulator of c-FLIPL proliferative role 
could help us understand if this phosphorylation could be a possible target for cancer therapy. 
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